Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease

Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease

ABSTRACT The present study aimed to establish a population pharmacokinetic (PopPK) modeling of benznidazole (BZD) in Brazilian patients with chronic Chagas disease. This was part of a Brazilian prospective cohort study with eight patients diagnosed with Chagas disease during the beginning of BZD treatment up to the 60th day. On the 15th day of treatment, a blood sampling was collected and analyzed. A one-compartment PK model was developed using Pmetrics. Patients with an average age of 50.3 (SD: 6.2) years old, 6 female patients and 2 males, 70.2 kg (14.2), receiving a 5 mg/Kg/day dose were included. PK parameters estimated for CL, V and Ka were 6.27 L/h, 38.97 L and 1.66 h-1, respectively. This is the first study to establish a population pharmacokinetic modeling of BZD in Brazilian patients with chronic Chagas disease. Therefore, further studies are needed to obtain the complete characterization of BZD pharmacokinetics.

Saved in:
Bibliographic Details
Main Authors: Frade,Virgínia Paula, Moreira,Carlos Henrique Valente, Sabino,Ester Cerdeira, Bedor,Danilo César Galindo, Ghilard,Fábio de Rose, Oliveira,Cláudia Di Lorenzo, Sanches,Cristina
Format: Digital revista
Language:English
Published: Instituto de Medicina Tropical de São Paulo 2022
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652022000100601
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT The present study aimed to establish a population pharmacokinetic (PopPK) modeling of benznidazole (BZD) in Brazilian patients with chronic Chagas disease. This was part of a Brazilian prospective cohort study with eight patients diagnosed with Chagas disease during the beginning of BZD treatment up to the 60th day. On the 15th day of treatment, a blood sampling was collected and analyzed. A one-compartment PK model was developed using Pmetrics. Patients with an average age of 50.3 (SD: 6.2) years old, 6 female patients and 2 males, 70.2 kg (14.2), receiving a 5 mg/Kg/day dose were included. PK parameters estimated for CL, V and Ka were 6.27 L/h, 38.97 L and 1.66 h-1, respectively. This is the first study to establish a population pharmacokinetic modeling of BZD in Brazilian patients with chronic Chagas disease. Therefore, further studies are needed to obtain the complete characterization of BZD pharmacokinetics.

Similar Items